Target Hospitality Announces Third Quarter 2026 Earnings Release and Conference Call Schedule
Original HTML

Target Hospitality Announces Third Quarter 2026 Earnings Release and Conference Call Schedule

THE WOODLANDS, Texas, Nov. 2, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (NASDAQ: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced that it will release its third quarter 2026 financial results before the market opens on Monday, November 9, 2026. The Company has also scheduled a conference call for Monday, November 9, 2026, at 9:00 am Eastern Time (8:00 am Central Time) to discuss the results.

The conference call will be available by live webcast through the Investors section of Target Hospitality's website at www.TargetHospitality.com.

Third Quarter 2026 Conference Call Information

Date:                Monday, November 9, 2026

Time:                9:00 am ET / 8:00 am CT

Direct Phone Dial: https://emportal.ink/4hxooaj

Traditional (operator-assisted)

Domestic:           1-800-836-8184

Please utilize the Direct Phone Dial option to be immediately entered into the conference call once you are ready to connect.

Please register for the webcast or dial into the conference call approximately 15 minutes before the scheduled start time.

A replay of the conference call will be available through the Investors section of Target Hospitality's website.

About Target Hospitality

Target Hospitality is one of North America's largest providers of vertically integrated specialty rental modular accommodations and full-service value-added hospitality solutions in the United States. Target builds, owns and operates a customized and growing network of communities for a range of end users through a full suite of value-added solutions, including premium catering and food services, maintenance, housekeeping, grounds-keeping, concierge, laundry services, logistics, security, recreational facilities services, community management, and community design and construction.

Investor Contact

Mark Schuck

(832) 702 - 8009      

[email protected]

SOURCE Target Hospitality

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302925776
Press Eligible
Yes
Press Eligible Reason
Company announcement scheduling its quarterly financial results and investor conference call.
Source Name
Unknown Company
Original Summary

<p>THE WOODLANDS, Texas, Nov. 2, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (NASDAQ: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced that...</p>

Content Hash (SHA-256, erste 32 hex)
26078dcce4bcd3ecc4c1283c23f7bd6a
ElektraFi Showcases Fixed Wireless Advantages Over Satellite Internet for Rural Colorado and Texas
Image File
Original HTML

Fiber-fed fixed wireless delivers lower latency, stronger upload capacity, and weather-resilient service as rural households compare Starlink and other low-earth-orbit (LEO) satellite options

GRANBY, Colo., Nov. 2, 2026 /PRNewswire/ -- ElektraFi, a rural broadband provider delivering high-speed fixed wireless and fiber-based internet to underserved communities in Colorado and Texas, today outlined the performance advantages of its fiber-fed fixed wireless network over Starlink and other low-earth-orbit (LEO) satellite internet services. ElektraFi serves Steamboat Springs and Granby, CO, Northeast Colorado, and the Denton suburbs in Texas.

As satellite internet is marketed to more rural households, ElektraFi is drawing attention to the technical factors that shape everyday performance: latency, upload capacity, connection consistency, network density, and weather resilience.

Rural households are often told satellite is their only option, and that simply isn't the case," said Ryan Jenkins, CEO of ElektraFi. "Fixed wireless fed by fiber gives families and businesses the responsiveness, upload capacity, and consistency that modern internet use demands, from gaming and video calls to streaming and content creation. And when customers need help, they reach a local team, not a mega-corp."

How Fixed Wireless Compares to LEO Satellite

- Lower latency: ElektraFi's fixed wireless typically delivers 10â20 milliseconds (ms) of latency, a noticeably snappier connection suited to online gaming and other real-time applications.

- Higher upload capacity: In many cases, fixed wireless offers greater upload capacity, making streaming and content creation much faster.

- Speed consistency: ElektraFi's network uses a fiber-fed connection that does not rely on transitioning from satellite to satellite, resulting in fewer interruptions.

- No density limitations: Due to physical beamwidth limitations, LEO satellite systems cannot serve more than a handful of customers per square mile without significant degradation in speed. Fixed wireless does not face that constraint.

- Less affected by weather: Fixed wireless remains reliable in the snow and during storms, a critical factor in Colorado's mountain communities.

- Local value: ElektraFi service is usually less expensive than satellite alternatives and is backed by a US-based customer support line from a local, state-based business.

Why It Matters

Download speed is only part of the picture. Latency and upload capacity increasingly determine how well a connection handles gaming, video calls, live streaming and content creation, all of which depend on fast, two-way traffic. Consistency matters just as much: a connection that drops during a satellite handoff or a snowstorm is a connection households and businesses cannot count on.

ElektraFi has built its network for resilience. In Routt and Moffat Counties, the company's network runs on premium generators and backup battery equipment, achieving 99.97% uptime in a region where power outages are routine.

Availability

Residents and businesses in Steamboat Springs, Granby, Northeast Colorado, and the Denton suburbs in Texas can check coverage and schedule installation at elektrafi.com or contact the Colorado sales team at (303) 241-4000.

About ElektraFi

ElektraFi is a rural broadband provider delivering high-speed fixed wireless and fiber-based internet to commonly underserved communities in Colorado and Texas. The company prioritizes local customer support, transparent pricing, and infrastructure built to serve real community needs. Learn more at elektrafi.com.

Media Contact

Jordan Freier

[email protected]

(303) 241-4000

Website: elektrafi.com

SOURCE ElektraFi, LLC

Share this article

Class (B2B/B2C)
B2C
Ingest Status
Rewritten
Dedupe hash
prn_302926139
Press Eligible
Yes
Press Eligible Reason
Manuelle Prüfung nötig. Risiko: MEDIUM. Flags: ['numbers']. Stichprobe: True
Source Name
Unknown Company
Original Summary

<p>Fiber-fed fixed wireless delivers lower latency, stronger upload capacity, and weather-resilient service as rural households compare Starlink and other low-earth-orbit (LEO) satellite options GRANBY, Colo., Nov. 2, 2026 /PRNewswire/ -- ElektraFi, a rural broadband provider delivering...</p>

Image URL
https://mmx.prnewswire.com/media/MS1974919/ElektraFi-LLC-Logo.jpg?id=OA3051480&p=facebook
Content Hash (SHA-256, erste 32 hex)
e7d2e231e8eeec99ebda13c1533c5448
MARITIME LAUNCH SERVICES RECEIVES FINAL APPROVAL TO LIST ON THE TORONTO STOCK EXCHANGE
Image File
Original HTML

Common shares to commence trading on TSX on November 3 under the symbol "MAXQ"

HALIFAX, NS, Nov. 2, 2026 /PRNewswire/ -- Maritime Launch Services Inc. (CBOE: MAXQ) (OTCQB: MAXQF) ("Maritime Launch" or the "Company"), developer of Spaceport Nova Scotia, today announced that, further to its press release dated October 14, 2026, it has received final approval from the Toronto Stock Exchange ("TSX") to list the Company's common shares (the "Common Shares").

The Common Shares will commence trading on the TSX at market open on November 3, 2026 under the symbol "MAXQ". In connection with the TSX listing, the Common Shares will cease trading on Cboe Canada at the close of trading on November 2, 2026.

The Company's CUSIP and ISIN numbers remain unchanged, and shareholders are not required to exchange their share certificates or direct registration system advices or take any other action in connection with the TSX listing.

"As Maritime Launch develops Spaceport Nova Scotia, Canada's gateway to space, listing on the Toronto Stock Exchange will provide an important platform to broaden our visibility and engagement with the investment community. We are building strategic national infrastructure that can connect Canada to the global space economy and provide sovereign access to space from Canadian soil. The TSX listing is another key milestone as we execute on that vision," said Stephen Matier, President and CEO of Maritime Launch.

About Maritime Launch Services

Maritime Launch Services Inc. is a Canadian-owned commercial space company based in Nova Scotia. Maritime Launch is developing Spaceport Nova Scotia, a dual-use commercial spaceport designed to support both civil and defence-related space missions. The spaceport will provide satellite launch services to domestic and international clients across the global commercial space market, supporting a wide range of orbital inclinations from a single location.

Spaceport Nova Scotia is Canada's first commercial orbital launch complex, enabling small and medium launch vehicles to place satellites into low Earth orbit.

For more information:

www.maritimelaunch.com

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "advance", "outlook", "objective", "develop", "opportunity", "potential", "growth", "milestone" "become", "expects", "anticipates", "continue", "intends", "estimates", "evolution", "projects", "strategy", "subject to", "believes", "plans", "seeks", "commit", "goal", "focus", "target", "vision" and similar expressions or variations of such words and phrases suggesting future outcomes or events, or which state that certain actions, events or results ''may'', "could", ''would'', "should" or ''will'' occur or be achieved are intended to identify forward-looking statements. In particular, statements regarding the anticipated timing of listing of securities on the TSX and delisting of securities on Cboe Canada, ticker symbols, CUSIP/ISIN numbers, steps to be taken by shareholders concerning the TSX listing, strategic vision and expectations of the Company following the TSX listing, and the expected benefits to the Company and its shareholders, and other stakeholders as a result of the TSX listing are or involve forward-looking statements. Such forward-looking information reflects management's current beliefs and is based on information currently available to management.

Forward-looking statements are based on a number of factors and assumptions which are subject to numerous risks and uncertainties, which have been used to develop such statements, but which may prove to be incorrect. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievement since such expectations are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Assumptions have been made regarding, among other things: the general stability of the economic and political environment in which the Company operates, general stability of the Canadian space exploration and defence industries, treatment under national security and regulatory regimes, securities laws and stock exchange policies, continuity of current Company management, the availability of suitable investment opportunities from capital markets, continuity of project development at Spaceport Nova Scotia, the ability of the Company and their respective service providers to obtain and retain qualified staff, equipment, materials and services in a timely and cost efficient manner, currency, foreign exchange and interest rates, global economic, financial markets and economic conditions, including the imposition of tariffs, in Canada and the United States.

The Company is subject to significant risks and uncertainties which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Such risk factors include, but are not limited to risk related to: material adverse changes in the affairs of the Company; adverse reactions or changes in business relations resulting from the announcement or completion of the TSX listing; disruption to supply chains; geographic concentration; current economic conditions including the imposition of tariffs; strategic initiatives; debt financing; interest rate fluctuations; foreign currency; competition in the space exploration and defence industries; reliance on key personnel; general uninsured losses; dependence on information technology; cyber security; integration of artificial intelligence; imposition of litigation; environmental matters and climate change; volatility of public markets and commodity prices; fluctuations in the trading price of the Company's securities; changes in legislation; dilution of securityholders; failure to obtain additional financing; potential conflicts of interest; and other risks described under the heading "Risk Factors" in the Company's current Annual Information Form and Management Discussion and Analysis, posted under its profile on SEDAR+ at www.sedarplus.ca.

The Company cannot assure investors that actual results will be consistent with any forward-looking statements and the Company assumes no obligation to update or revise such forward-looking statements to reflect actual events or new circumstances other than as required by applicable securities laws. All forward-looking statements contained in this press release are qualified by this cautionary statement.

SOURCE Maritime Launch Services Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302925651
Press Eligible
Yes
Press Eligible Reason
Company announcement about its TSX listing and trading commencement.
Source Name
Unknown Company
Original Summary

<p>Common shares to commence trading on TSX on November 3 under the symbol "MAXQ" HALIFAX, NS, Nov. 2, 2026 /PRNewswire/ -- Maritime Launch Services Inc. (CBOE: MAXQ) (OTCQB: MAXQF) ("Maritime Launch" or the "Company"), developer of Spaceport Nova Scotia, today announced that, further to its...</p>

Image URL
https://mmx.prnewswire.com/media/MS1861559/Maritime-Launch-Services-Inc-MARITIME-LAUNCH-SERVICES-RECEIVES.jpg?id=OA3050984&p=facebook
Content Hash (SHA-256, erste 32 hex)
33c0fbc999df8bdb05db6d5c84744313
Tactical Communication Market worth $19.39 billion by 2031 - Exclusive Report by MarketsandMarkets™
Image File
Original HTML

DELRAY BEACH, Fla., Nov. 2, 2026 /PRNewswire/ -- According to MarketsandMarketsâ¢, the tactical communication market is projected to grow from USD 13.14 billion in 2026 to USD 19.39 billion by 2031 at a CAGR of 8.1%.

Browse 525 market data Tables and 68 Figures spread through 602 Pages and in-depth TOC on 'Tactical Communication Market - Global Forecast to 2031'

Tactical Communication Market Size & Forecast:

- Market Size Available for Years: 2021â2031

- 2026 Market Size: USD 13.14 billion

- 2031 Projected Market Size: USD 19.39 billion

- CAGR (2026â2031): 8.1%

Tactical Communication Market Trends & Insights:

- The market for tactical communication is gaining traction due to the increasing need for security, resilience, and interoperability in battlefield communications, increasing defense modernization efforts, and increased use of network-centric warfare concepts. Increasing need for tactical radios, backbone & backhaul systems, tactical SATCOM systems, intercommunication systems, network infrastructure, private wireless systems, and communication headsets. The increased use of software-defined radios, MANET, deployable LTE/5G, SATCOM on the move, and multi-bearer networking is further driving the growth of the market.

- By equipment type, tactical radio systems are expected to account for the largest market share, while tactical private wireless systems are expected to register the highest CAGR (13.3%) during the forecast period.

- By platform, land is expected to register strong growth of 47.78% during the forecast period.

- By frequency band, single band is expected to account for the largest market share during the forecast period.

- By application, command and control communications is expected to account for the largest market share during the forecast period.

- By end user, army/land forces are expected to account for the largest share of the tactical communication market.

- By region, Europe is projected to have the highest CAGR of 9.2% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255957957

The tactical communication market growth can be attributed to the rise in the use of secure, reliable, and interoperable communications solutions for the military that aid in enhancing command and control, situational awareness, coordination of missions, and battlefield communications. The use of tactical radios, satellite communication terminals, tactical networks, and intercommunications solutions on dismounts, land vehicles, aircraft, naval platforms, and unmanned aerial vehicles by the army, air force, navy, special operations, and joint forces is becoming more prevalent. Other drivers include modernization of defense forces, replacement of existing communication solutions, network-centric operations, and connected battlefield platforms.

Development of software-defined radio, multiband communications, MANET-based networking, secure waveforms, tactical satellite communications, deployable LTE/5G, encryption technologies, and multi-bearer network architecture is becoming a critical area of technological innovation in this market. This is improving the capability of tactical communication systems to ensure secure voice and data communication among dispersed forces in contested electromagnetic environments. It is also helping in achieving interoperability, network resilience, higher data throughput, lower communication latency, and better connectivity among soldiers, command centers, sensors, and manned/unmanned systems.

By equipment type, the tactical private wireless systems segment is positioned for strong advancement during the forecast period.

There are chances that tactical private wireless systems will experience considerable gains in the tactical communication market owing to increasing use of private LTE, private 5G, and hybrid multi-technology wireless communication by the defense organizations within forward operating bases, command centers, logistics centers, vehicles, and other tactical environments. Increasing needs for high-capacity data communication, real-time video, sensor communication, mission-specific applications, and broadband communication have been propelling the market for quickly deployable private wireless communication infrastructure. Increased use of private wireless networks in combination with tactical radios, satellite communication, command and control communication, edge computing platforms, and unmanned systems has been driving the acceptance of the technology.

There has been growing development in 5G-based tactical networking, network slicing, edge computing, multi-bearer communication, and resilient mesh architectures. These technologies enable defense forces to create localized, scalable, and secure communication networks in areas where fixed communication infrastructure is absent or has been disrupted.

By end user, the army/land forces segment is projected to represent significant demand during the forecast period.

Both army and land forces are expected to provide considerable demand for the tactical communication market as secure, robust, and interoperable communication solutions are used by defense establishments in their operations on dismounted troops, ground combat vehicles, tactical/utility/support vehicles, and command posts. Land forces utilize tactical radios, tactical backbone/backhaul, SATCOM terminals, intercommunication systems, tactical networks, and private wireless networks in order to achieve command and control, situational awareness, mission coordination, and communications within these processes, especially in dispersed and contested environments where connectivity is important. Soldier modernization, radio replacement, network-centric warfare, and more integration between communication solutions within the vehicles and battlefield command posts are fueling the market demand even further. This adoption process is also assisted by software-defined radios, multiband communication, MANET-based networking, secure waveforms, anti-jam capabilities, tactical SATCOM, and deployable LTE/5G networks that allow the army and land forces to enhance their communication capabilities, interoperability, data transfer, and mission effectiveness through tactical communication solutions.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=255957957

Increasing growth opportunities are expected from the Europe region during the forecast period.

An increase in defense modernization and development initiatives related to NATO interoperability, network-centric warfare, and battlefield communication infrastructure in European countries would create growth opportunities for the tactical communication industry. Procurement and upgrades of tactical radio systems, tactical satellite communications (SATCOM) terminals, tactical backbone and backhaul systems, tactical intercommunications systems, tactical network infrastructure, and private wireless networks have become increasingly important in Germany, the UK, France, Poland, Italy, Spain, and other European countries. Growing security issues associated with the Russia-Ukraine conflict, the modernization of military communications networks, and the strengthening of NATO's eastern flank would be key factors fueling demand for tactical communication equipment that is resilient, interoperable, and secure. Furthermore, the increased use of software-defined and multiband radios, mobile ad hoc networking (MANET), encrypted military waveforms, anti-jamming communication technology, and deployable LTE/5G networks would aid battlefield communication among land, air, and naval forces. Investments in joint military operations, cross-border interoperability, and the integration of tactical communication equipment with battlefield management systems and unmanned systems would continue to drive the tactical communication market in Europe during the forecast period.

The most influential companies in the Tactical Communication companies are L3 Harris Technologies, Inc. (based in the US), Thales (France), Elbit Systems Ltd (Israel), Aselsan AS (Turkey), Rheinmetall AG Ltd. (Germany), Bharat Electronics Limited (BEL) (India), Viasat (US), DTC â A Codan Company (US), Rafael Advanced Defense Systems Ltd (Israel) and Nokia Corporation (Finland). The competitive environment within the tactical communication market includes defense communications original equipment manufacturers (OEMs) and specialist providers that operate in the sectors of tactical radio systems, tactical backbone/backhaul systems, tactical satellite communication (SATCOM) systems, tactical intercommunication systems, tactical networking infrastructure, tactical private wireless systems, and tactical communication headsets and control units. Competition among the players revolves around the provision of secure and robust communication solutions, software-defined and multiband radios, high-capacity tactical backhaul, SATCOM, inter-platform communication, routing and gateway solutions, deployable LTE/5G networks, interoperability and anti-jamming solutions.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302926235
Press Eligible
Yes
Press Eligible Reason
Manuelle Prüfung nötig. Risiko: MEDIUM. Flags: ['numbers', 'finance']. Stichprobe: False
Source Name
Tactical Communication Market worth $19.39 billion by 2031
Original Summary

<p>DELRAY BEACH, Fla., Nov. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the tactical communication market is projected to grow from USD 13.14 billion in 2026 to USD 19.39 billion by 2031 at a CAGR of 8.1%. Browse 525 market data Tables and 68 Figures spread through 602 Pages and...</p>

Image URL
https://mmx.prnewswire.com/media/MS1173081/MarketsandMarkets-Logo.jpg?id=OA3051835&p=facebook
Content Hash (SHA-256, erste 32 hex)
e1b51413e832a3c6006dbdc4a532a637
Former EY U.S. CEO Julie Boland joins Deere & Company's Board of Directors
Image File
Original HTML

Former EY U.S. CEO Julie Boland joins Deere & Company's Board of Directors

MOLINE, Ill., Nov. 2, 2026 /PRNewswire/ -- Deere & Company (NYSE: DE) today announced the appointment of Julie Boland, former U.S. chief executive officer and managing partner and Americas managing partner of Ernst & Young LLP (EY), to its board of directors. Boland brings extensive executive leadership experience and deep expertise in accounting, financial reporting, corporate governance, and global finance.

"Julie's proven leadership, financial acumen, and governance expertise make her a strong addition to our board," said John C. May, chairman and CEO of Deere & Company. "Her record leading a complex global organization, together with her finance and investment banking background, will sharpen the board's perspective as Deere executes its strategy, accelerates long-term growth, and delivers value for customers and shareholders."

Boland served as EY's U.S. chief executive officer and managing partner and Americas managing partner from 2022 to 2026, culminating more than 16 years with the firm in roles of increasing responsibility. Her previous leadership positions included vice chair and Central Region managing partner and Cleveland office managing partner.

Before joining EY, Boland was chief financial officer at public and private companies and worked in investment banking at JPMorgan & Co. and Goldman Sachs in New York, Chicago, and London. Her experience spans financial leadership, enterprise strategy and transformation, capital allocation, regulatory affairs, risk management, and international banking.

Boland's appointment expands Deere's board from 10 to 11 members, including 10 independent, non-employee directors.

About Deere & Company

It doesn't matter if you've never driven a tractor, mowed a lawn, or operated a dozer. With John Deere's role in helping produce food, fiber, fuel, and infrastructure, we work for every single person on the planet. It all started nearly 200 years ago with a steel plow. Today, John Deere drives innovation in agriculture, construction, forestry, turf, power systems, and more.

SOURCE John Deere Company

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302923974
Press Eligible
Yes
Press Eligible Reason
Corporate board appointment and executive leadership news.
Source Name
Unknown Company
Original Summary

<p>MOLINE, Ill., Nov. 2, 2026 /PRNewswire/ -- Deere & Company (NYSE: DE) today announced the appointment of Julie Boland, former U.S. chief executive officer and managing partner and Americas managing partner of Ernst & Young LLP (EY), to its board of directors. Boland brings extensive...</p>

Image URL
https://mmx.prnewswire.com/media/MS2023728/Boland-Julie_ProfileSquare.jpg?id=OA3047834&p=facebook
Content Hash (SHA-256, erste 32 hex)
dd6aca128347d23d48e05c9a1ce4d403
OncoC4 Appoints Dr. Dan Janiak as Chief Business Officer
Image File
Original HTML

ROCKVILLE, Md., Nov. 2, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and immunological diseases, today announced the appointment of Dr. Dan Janiak as Chief Business Officer.

Dan brings more than 15 years of experience building, financing, and scaling biotechnology companies across oncology, neurology, and rare diseases. His background spans corporate strategy, business development, venture investing, and new company formation. Most recently, he served as Executive Director, Business Development at AstraZeneca, where he led oncology platform transactions involving artificial intelligence, machine learning, and enabling technologies.

"We are delighted to welcome Dan to OncoC4 at an important stage in the Company's growth," said Yang Liu, Ph.D., Co-founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. "Dan brings a rare combination of scientific understanding, strategic judgment and transaction experience across both emerging biotechnology companies and global biopharmaceutical organizations. His experience building partnerships, executing complex transactions and developing corporate strategy will be highly valuable as we continue to advance our pipeline and pursue opportunities to maximize the value of our innovative therapies for patients."

Prior to joining AstraZeneca, Dan served as President and Chief Operating Officer of Trotana Therapeutics. Before joining Trotana, Dan was the first employee of Taysha Gene Therapies, where he served as Senior Vice President of Corporate Strategy and Business Development and helped build the company from its inception.

Earlier in his career, Dan held strategy and corporate development roles at VelosBio and AveXis. He began his career in venture investing and new company creation at Mercury Fund and In-Q-Tel, where he managed investments across therapeutics and medical technologies and advised numerous emerging biopharmaceutical companies.

"OncoC4 has built a compelling portfolio of innovative oncology and immunology programs, and I am excited to join the company at this important point in its evolution," said Dan Janiak, Ph.D., Chief Business Officer of OncoC4. "I look forward to working with Yang and the leadership team to advance OncoC4's business development and corporate strategy, build strategic partnerships, and create opportunities that can accelerate the company's programs and bring new therapies to patients."

Dan is a Kauffman Fellow and earned a Ph.D. from the University of Maryland, College Park where he held the Fischell Fellowship in Biomedical Engineering.

About OncoC4

Headquartered in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the treatment of cancer and immunological diseases, including neurodegenerative diseases. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well-validated targets across oncology and immunological diseases. Among them, cesalatamig is a wholly owned and highly differentiated PD-1/VEGF bispecific antibody currently undergoing rapid global clinical development in multiple oncology indications. Tasafustobart (ONC-841) is a first-in-class anti-SIGLEC-10 antibody currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative diseases. In addition, OncoC4 recently initiated a first-in-human trial of ONC-783, a first-in-class T cell engager targeting a novel CD24 epitope selectively expressed across a broad spectrum of human cancers, including solid tumors and hematological malignancies, in the United States. OncoC4 has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316/ONC-392), a tumor microenvironment-selective Treg depletion candidate targeting CTLA-4, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer.

For more information, please visit www.oncoc4.com

Contacts

Media Relations

[email protected]

Investor Relations

[email protected]

SOURCE OncoC4

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302925797
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): Target states 'OncoC4's lead asset, cesalatamig...' but the source does not call cesalatamig the lead asset; it lists it 'Among' pipeline assets. This is an unsupported factual claim.
Source Name
Unknown Company
Original Summary

<p>ROCKVILLE, Md., Nov. 2, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and immunological diseases, today announced the appointment of Dr. Dan Janiak as Chief Business Officer. Dan brings more than 15 years of...</p>

Image URL
https://mmx.prnewswire.com/media/MS1732834/OncoC4-Logo.jpg?id=OA3051390&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "OncoC4 Names Ex-AstraZeneca Dealmaker Dan Janiak Chief Business Officer", "body_html": "<p><strong>ROCKVILLE -- [CURRENT_DATE] --</strong> OncoC4, a privately held, late clinical-stage biopharmaceutical company, has appointed Dr. Dan Janiak as Chief Business Officer, adding a executive with more than 15 years of biotech financing and deal experience as it advances its oncology and immunology pipeline.</p><h5>Janiak led oncology platform transactions at AstraZeneca</h5><p>Janiak most recently served as Executive Director, Business Development at AstraZeneca. There he led oncology platform transactions involving artificial intelligence, machine learning and enabling technologies.</p><p>Before AstraZeneca, he was President and Chief Operating Officer of Trotana Therapeutics. He was also the first employee of Taysha Gene Therapies, where he served as Senior Vice President of Corporate Strategy and Business Development and helped build the company from inception. Earlier roles included strategy and corporate development positions at VelosBio and AveXis, and venture investing and new company creation at Mercury Fund and In-Q-Tel.</p><h5>OncoC4 CEO Yang Liu cites transaction experience as the hiring driver</h5><p>Co-founder, CEO and Chief Scientific Officer Yang Liu, Ph.D., pointed to Janiak's \"rare combination of scientific understanding, strategic judgment and transaction experience.\" Liu said his partnership-building and corporate strategy background will support the advancement of the company's pipeline and efforts to maximize the value of its therapies.</p><p>Janiak will work with Liu and the leadership team on business development, corporate strategy and strategic partnerships.</p><h5>Late-stage pipeline includes a wholly owned PD-1/VEGF bispecific</h5><p>OncoC4's lead asset, cesalatamig, is a wholly owned PD-1/VEGF bispecific antibody in global clinical development across multiple oncology indications. Tasafustobart (ONC-841), an anti-SIGLEC-10 antibody, is in a Phase 2 oncology trial and a Phase 1 trial in neurodegenerative diseases. The company recently started a first-in-human trial in the United States of ONC-783, a T cell engager targeting a novel CD24 epitope.</p><p>OncoC4 also has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316/ONC-392), a CTLA-4-targeting Treg depletion candidate, in multiple solid tumor indications. The program includes an ongoing pivotal trial in squamous non-small cell lung cancer.</p><p>Janiak is a Kauffman Fellow and holds a Ph.D. from the University of Maryland, College Park, where he held the Fischell Fellowship in Biomedical Engineering.</p>", "meta_description": "OncoC4 appoints Dr. Dan Janiak, formerly of AstraZeneca, as Chief Business Officer to drive partnerships and strategy for its late-stage oncology pipeline.", "seo_keywords": "OncoC4, Dan Janiak, Chief Business Officer, AstraZeneca, biopharmaceutical, oncology, cesalatamig, BioNTech, business development, executive appointment", "companies": ["OncoC4", "AstraZeneca", "BioNTech"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["executive_appointment"], "products": ["cesalatamig"], "themes": ["leadership_change", "business_development", "oncology_pipeline"], "events": [], "cta_text": "Learn more about OncoC4's oncology and immunology pipeline", "learn_more": "https://www.oncoc4.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
9cdd92646c37d7cc61f97da72279bfad
TD Brings its Global Asset Management Businesses Under One Name
Original HTML

TD Brings its Global Asset Management Businesses Under One Name

TD Global Investment Solutions will become TD Asset Management, simplifying how clients engage with the firm globally

TORONTO, Nov. 2, 2026 /PRNewswire/ -- TD Global Investment Solutions will now operate under the TD Asset Management (TDAM) name, creating one consistent global brand across the firm's institutional and retail asset management businesses. Additionally, Epoch Investment Partners, Inc. (TD Epoch) has changed its name to TD Asset Management (US) Inc. (TDAM US). Both TD Asset Management Inc. and TDAM US will offer their products and services under the TDAM name. The change applies across all markets and jurisdictions, bringing TDAM's asset management capabilities together under one global brand.

"Our unified brand creates a clearer market presence and a more consistent experience for our clients around the world," says David Sykes, Chief Executive Officer, TDAM and Executive Vice President, TD Bank Group. "By bringing our capabilities under one name, we can make it easier for clients to understand and access the breadth of investment expertise we offer."

Key Takeaways:

- TD Global Investment Solutions will operate under the TDAM name.

- TD Epoch has changed its name to TDAM US.

- Under one brand, TDAM will continue to leverage its global capabilities to deliver disciplined investment management.

- Our unified brand creates a clearer market presence and more consistent experience for clients globally.

A simpler, more connected experience for clients

These changes do not affect TDAM's investment approach. Investment teams, portfolio managers, investment philosophies, and service teams remain unchanged.

"Our focus at TDAM has always been to put our clients at the centre of everything we do. That commitment is reflected in how we innovate, pursue investment excellence and build strong relationships to tailor solutions that aim to deliver better outcomes and help clients achieve their investment goals," says Sykes.

Building on a legacy of trusted investment expertise

With over 35 years of investment experience, TDAM offers fundamental equity strategies, including free cash flow strategies, quantitative and passive equities, fixed income across credit qualities, global multi-asset and derivatives solutions, commodities, and, in certain jurisdictions, private markets, including real estate, infrastructure, private debt and mortgages.

Under the unified brand, TDAM will continue to deliver disciplined investment management and draw on its global capabilities to support a broad range of investment objectives.

FAQ:

What is changing across TD Asset Management?

We will now operate under a unified global brand, effective October 30, 2026. There will be no changes to TDAM's investment approach, investment teams, portfolio managers, investment philosophies, and service teams.

Why is this change happening?

A unified brand creates a clearer market presence for our clients around the world.

Will the change impact any investment offerings?

These changes do not affect the management of assets or the firm's investment approach. Investment teams, portfolio managers, investment philosophies, and service teams remain unchanged.

About TD Asset Management

TD Asset Management (TDAM) is a global asset manager committed to helping clients achieve their investment objectives1. We are proud to serve institutional, intermediary and individual investors with solutions designed to address their evolving needs. Our specialized expertise and diverse perspectives enable us to navigate changing markets while pursuing long-term outcomes. TDAM offers a broad range of investment capabilities across public and private markets: fundamental equity strategies such as free cash flow-driven approaches, quantitative and passive equities; fixed income mandates across the credit quality spectrum; and alternative offerings such as commodities.

1 TD Asset Management represents TD Asset Management Inc. which operates in Canada and TD Asset Management (US), Inc. which operates in the U.S. Both entities are affiliates and wholly-owned subsidiaries of The Toronto-Dominion Bank. TD Asset Management products are also available through a network of affiliated and unaffiliated distributors. Please contact our distribution partners to find out more.

The information contained herein is for information purposes only. The information has been drawn from sources believed to be reliable. The information does not provide financial, legal, tax, accounting or investment advice. Particular investment, tax or trading strategies should be evaluated relative to each individual's objectives and risk tolerance. This material is not an offer to any person in any jurisdiction where unlawful or unauthorized. These materials have not been reviewed by and are not registered with any securities or other regulatory authority in jurisdictions where we operate. Any general discussion or opinions contained within these materials regarding securities, real assets or market conditions represent our view or the view of the source cited. Unless otherwise indicated, such view is as of the date noted and is subject to change. Information about the portfolio holdings, asset allocation or diversification is historical and is subject to change.

® The TD logo and other TD trademarks are the property of The Toronto-Dominion Bank or its subsidiaries.

For further information: Jillian Tanouye, TD Bank Group, [email protected]

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302925321
Press Eligible
Yes
Press Eligible Reason
TD is consolidating its global asset management businesses under one brand, a corporate and financial services announcement.
Source Name
Unknown Company
Original Summary

<p>TD Global Investment Solutions will become TD Asset Management, simplifying how clients engage with the firm globally TORONTO, Nov. 2, 2026 /PRNewswire/ -- TD Global Investment Solutions will now operate under the TD Asset Management (TDAM) name, creating one consistent global brand...</p>

Content Hash (SHA-256, erste 32 hex)
daadec87c4899230f623c774cde2a366
Marriott International Reports Third Quarter 2026 Results
Image File
Original HTML

- Third quarter 2026 RevPAR1 increased 6.5 percent worldwide, with 7.4 percent growth in the U.S. & Canada and 4.4 percent growth in international markets

- Third quarter reported diluted EPS totaled $3.04 and Adjusted diluted EPS totaled $3.02

- Third quarter reported net income totaled $794 million and Adjusted net income totaled $790 million

- Third quarter Adjusted EBITDA totaled $1,512 million

- The company added roughly 20,100 net rooms globally during the quarter and net rooms grew 4.6 percent from the end of the third quarter of 2025

- At the end of the quarter, Marriott's worldwide development pipeline reached a new record and totaled over 4,200 properties and more than 634,000 rooms, with 44 percent of pipeline rooms under construction including hotels that are pending conversion

- The company repurchased 3.5 million shares of common stock for $1.3 billion in the 2026 third quarter. Year-to-date through October 28, the company has returned approximately $4.0 billion to shareholders through dividends and share repurchases

For a summary of third quarter 2026 highlights, please visit: https://news.marriott.com/static-assets/component-resources/newscenter/earnings/2026/2026-q3-earnings-infographic.pdf.

BETHESDA, Md., Nov. 2, 2026 /PRNewswire/ -- Marriott International, Inc. (Nasdaq: MAR) today reported third quarter 2026 results.

Anthony Capuano, President and Chief Executive Officer, said, "Our excellent third quarter results reflected continued momentum across our business, the benefits of our global scale, and the power of our brands and revenue engines. Global RevPAR increased 6.5 percent in the third quarter, on higher ADR and occupancy. In the U.S. & Canada, RevPAR rose over 7 percent, with broad-based growth across customer segments and chain scales.

"International RevPAR increased over 4 percent in the quarter, led by APEC, which delivered over 9 percent RevPAR growth, supported by robust international inbound demand. EMEA RevPAR rose over 4 percent, thanks to solid growth in Europe. While the ongoing conflict in the Middle East continued to impact results in that region, trends improved meaningfully from the second quarter. For full year 2026, given our strong third quarter performance and expectations for continued healthy demand, we are raising our global RevPAR outlook and now expect growth of 4.5 to 5 percent.

"Our development activity remained strong, and we had record global organic signings year to date through September. Conversions continued to be an important driver of growth, representing over a third of signings and over 40 percent of openings during the first nine months of the year.

"Marriott Bonvoy continued to expand its reach and deliver value to our owners and properties and across the enterprise. Our broad portfolio of brands and experiences and powerful collaborations with Uber, Starbucks and others helped drive membership to approximately 309 million members around the world at quarter-end.

"Our global scale, compelling portfolio of brands, industry-leading Marriott Bonvoy loyalty program and dedicated associates, together with our robust development pipeline and disciplined execution, give us confidence in our ability to deliver sustainable, long-term growth."

Third Quarter 2026 Results

Franchise and base management fees totaled $1,341 million in the 2026 third quarter, a 13 percent increase compared to franchise and base management fees of $1,190 million in the year-ago quarter. The increase was primarily driven by higher co-branded credit card fees, higher RevPAR and rooms growth.

Incentive management fees totaled $181 million in the 2026 third quarter, a 22 percent increase over $148 million in the 2025 third quarter. All regions posted positive growth year over year, with incentive fees in the U.S. & Canada up meaningfully.

Owned, leased, and other revenue, net of owned, leased, and other expense2, totaled $41 million in the 2026 third quarter, compared to $70 million in the 2025 third quarter. The decline reflected lower owned and leased hotel results, including the impact of renovations and our 2026 second quarter sale of a U.S. & Canada hotel, and higher costs associated with a third-party agreement, partially offset by a $12 million expected insurance recovery associated with the 2026 second quarter property-related litigation matter ($9 million after-tax impact and $0.03 per share after-tax).

General and administrative expenses2 for the 2026 third quarter totaled $214 million, compared to $210 million in the year-ago quarter.

Interest expense, net, totaled $219 million in the 2026 third quarter, compared to $194 million in the year-ago quarter. The increase was primarily due to higher interest expense associated with higher debt balances.

In the 2026 third quarter, the provision for income taxes totaled $266 million, flat compared to the year-ago quarter.

Marriott's reported operating income totaled $1,274 million in the 2026 third quarter, compared to 2025 third quarter reported operating income of $1,180 million. Reported net income totaled $794 million in the 2026 third quarter, a 9 percent increase compared to 2025 third quarter reported net income of $728 million. Reported diluted earnings per share (EPS) totaled $3.04 in the quarter, compared to reported diluted EPS of $2.67 in the year-ago quarter.

Adjusted operating income in the 2026 third quarter totaled $1,267 million, compared to 2025 third quarter Adjusted operating income of $1,119 million. Third quarter 2026 Adjusted net income totaled $790 million, compared to 2025 third quarter Adjusted net income of $674 million. Adjusted diluted EPS in the 2026 third quarter totaled $3.02, compared to Adjusted diluted EPS of $2.47 in the year-ago quarter.

Third quarter 2026 Adjusted results excluded cost reimbursement revenue, reimbursed expenses, and certain impairment charges. See the press release schedules for the calculation of Adjusted results and the manner in which the Adjusted measures are determined in this press release.

Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) totaled $1,512 million in the 2026 third quarter, a 12 percent increase compared to third quarter 2025 Adjusted EBITDA of $1,349 million. See the press release schedules for the Adjusted EBITDA calculation.

Income Statement Reclassification

In the 2025 fourth quarter, to enhance understanding of the company's general and administrative costs, we reclassified amounts attributable to other expenses previously reported under the "General, administrative, and other" caption to the "Owned, leased, and other expense" caption of our Income Statements. The expenses that were reclassified from "General, administrative, and other" are certain costs associated with our property-related fee revenues, such as guarantee expense, provision for credit losses, and certain brand-related or property-related expenses, as well as costs associated with certain third-party agreements. Please refer to the Expense Captions - As Reclassified section in the press release schedules for information about the affected expense captions, as reclassified, for each quarter and the full fiscal year of 2025.

Selected Performance Information

The company added roughly 20,100 net rooms during the quarter, including over 13,400 net rooms in international markets. At the end of the quarter, Marriott's global system totaled over 10,200 properties, with nearly 1,834,000 rooms.

At the end of the quarter, the company's worldwide development pipeline totaled 4,209 properties with more than 634,000 rooms, including 266 properties with over 37,000 rooms approved for development but not yet subject to signed contracts. The quarter-end pipeline included 1,750 properties with over 278,000 rooms under construction, including hotels that are in the process of converting to our system. Over half of the rooms in the quarter-end pipeline were located in international markets.

In the 2026 third quarter, worldwide RevPAR increased 6.5 percent (a 6.4 percent increase using actual dollars) compared to the 2025 third quarter. RevPAR in the U.S. & Canada increased 7.4 percent (a 7.3 percent increase using actual dollars), and RevPAR in international markets increased 4.4 percent (a 4.4 percent increase using actual dollars) compared to the 2025 third quarter.

Balance Sheet & Common Stock

At the end of the quarter, Marriott's total debt was $16.8 billion and cash and equivalents totaled $0.5 billion, compared to $16.2 billion in debt and $0.4 billion of cash and equivalents at year-end 2025.

The company repurchased 3.5 million shares of common stock in the 2026 third quarter for $1.3 billion. Year-to-date through October 28, the company has repurchased 9.6 million shares for $3.4 billion.

During the 2026 third quarter, the company issued $250 million of Series NN Senior Notes due in 2029 with a 4.875 percent interest rate coupon and $1.0 billion of Series YY Senior Notes due in 2036 with a 5.650 percent interest rate coupon. The company also completed the refinancing of its credit facility, extending the maturity to September 2031 and increasing the facility size from $4.5 billion to $5.0 billion.

Company Outlook

The company's updated outlook generally assumes the continuation of the current macroeconomic environment. 

Marriott International, Inc. (Nasdaq: MAR) will conduct its quarterly earnings review for the investment community and news media on Monday, November 2, 2026, at 8:00 a.m. Eastern Time (ET). The conference call will be webcast simultaneously via Marriott's investor relations website at www.marriott.com/investor (click on "Events & Presentations" and click on the quarterly conference call link). A replay will be available at that same website until November 2, 2027.

The telephone dial-in number for the conference call is US Toll Free: 833-309-3473, or Global: +1 785-838-9251. The conference ID is MAR3Q26.

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302925186
Press Eligible
Yes
Press Eligible Reason
Manuelle Prüfung nötig. Risiko: MEDIUM. Flags: ['finance', 'numbers']. Stichprobe: False
Source Name
Unknown Company
Original Summary

<p>Third quarter 2026 RevPAR1 increased 6.5 percent worldwide, with 7.4 percent growth in the U.S. & Canada and 4.4 percent growth in international markets Third quarter reported diluted EPS totaled $3.04 and Adjusted diluted EPS totaled $3.02 Third quarter reported net income totaled $794...</p>

Image URL
https://mmx.prnewswire.com/media/MS201796/Marriott-International-logo-black.jpg?id=OA3049756&p=facebook
Content Hash (SHA-256, erste 32 hex)
6b005faab1896ea118a63dc84594efb2
Protego to Highlight PROT-001's Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026
Image File
Original HTML

- Phase 1 results in healthy volunteers characterize the clinical profile of PROT-001, an investigational first-in-class lambda light chain kinetic stabilizer

- Preclinical presentations to evaluate PROT-001's potential to reduce light chain-induced cardiac toxicity in AL amyloidosis and its compatibility with bortezomib-based treatment

- AmyLiteDx⢠Assay and presentations that highlight advances in pharmacodynamic and clinical activity measures for PROT-001 development

SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding diseases, today announced five presentations at the XX International Symposium on Amyloidosis (ISA 2026), taking place November 15â18, 2026.

The presentations follow the company's recently announced FDA clearance to proceed with its Phase 2/3 SHIELD-AL study, which will evaluate PROT-001 added to standard of care in patients with AL amyloidosis.

"PROT-001 was designed to stabilize amyloidogenic light chains and neutralize their toxicity, providing a distinct approach that could complement therapies directed at the plasma cells that produce them," said Brent J. Warner, MBA, Chief Executive Officer of Protego. "As we initiate SHIELD-AL, we believe our approach could help patients achieve faster and deeper organ responses beyond standard of care alone. Deeper cardiac responses are associated with improved survival, underscoring the potential of PROT-001 to make a meaningful difference for patients."

Protego's presentations at ISA 2026 will include four Discussed E-poster presentations and one traditional poster presentation:

Title: PROT-001, a first in class lambda light chain kinetic stabilizer for AL amyloidosis: Results from the Phase I PRO-1A-101 Study

- Abstract Number: 32458

- Session: E-poster Session 1 - Treatments of AL

- Presentation Date and Time: Monday, November 16, 2026; 10:35 AM - 11:00 AM

Title: PROT-001 Demonstrates Compatibility with Bortezomib-Based Regimens While Preserving Plasma Cell Cytotoxicity

- Abstract Number: 32147

- Session: E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses

- Presentation Date and Time: Tuesday, November 17, 2026; 11:00 AM - 12:00 PM

Title: PROT-001 Suppresses Amyloidogenic Light Chain Induced BNP Signaling and Cardiotoxicity in Human Cardiomyocytes

- Abstract Number: 32266

- Session: E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses

- Presentation Date and Time: Tuesday, November 17, 2026; 11:00 AM - 12:00 PM

Title: AmyLiteDx: A Mass Spectrometry-Based Platform for Sensitive and In-Depth Analysis of Amyloidogenic Immunoglobulin Light Chains in AL Amyloidosis

- Abstract Number: 32645

- Session: E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses

- Presentation Date and Time: Tuesday, November 17, 2026; 11:00 AM - 12:00 PM

Title: Retrospective Study Evaluating Cardiac Biomarkers in Patients with AL Cardiac Amyloidosis

- Abstract Number: 32646

- Session: General Poster Session

- Presentation Date and Time: Tuesday, November 17, 2026

About Protego Biopharma

Protego Biopharma is a clinical-stage biotechnology company developing first-in-class small molecule therapies for AL amyloidosis and other protein misfolding diseases. Protego aims to translate advances in protein stabilization into medicines that address the misfolding and toxicity responsible for progressive organ damage. Its therapies are designed to intervene in this disease process, with the goal of preserving organ function and improving patients' lives. For more information, visit www.protegobio.com.

About PROT-001

PROT-001 is Protego Biopharma's lead investigational small molecule pharmacological chaperone, being developed for the treatment of immunoglobulin light chain (AL) amyloidosis. PROT-001 is designed to stabilize amyloidogenic lambda light chain proteins and prevent their misfolding and the formation of proteotoxic species. The goal of this therapy is limiting the toxic effects that contribute to organ injury, including direct damage to cardiomyocytes in AL patients. PROT-001 represents a complementary approach to plasma cell-directed therapies, which reduce light chain production. By targeting the amyloidogenic light chain protein itself before it can adopt a pathogenic conformation, PROT-001 has the potential to complement existing treatments and address an additional mechanism of disease.

About the Phase 1 PRO-1A-101 Study

PRO-1A-101 was a first-in-human, randomized, double-blind, placebo-controlled four-part Phase 1 study that evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), food effect (FE), and drug-drug interaction (DDI) potential of PROT-001 in healthy adult participants. Part 1 was a single ascending dose (SAD) study. Part 2 was a multiple ascending dose (MAD) study. Part 3 was a non-randomized FE cross-over study. Part 4 was a non-randomized, open-label study that evaluated potential precipitant DDIs of PROT-001. Additional information on this study can be found on ClinicalTrials.gov under the identifier NCT06981299.

About AL Amyloidosis

Immunoglobulin light chain (AL) amyloidosis is a rare, life-threatening disease affecting over 5,100 newly diagnosed patients annually and 28,000 US adults in which abnormal plasma cells produce light chain proteins that can misfold and aggregate. The direct toxicity of disease-related light chains and their accumulation as amyloid deposits in tissues both result in injury to organs, including the heart and kidneys. Cardiac injury is particularly serious, as toxic light chains can directly impair cardiomyocyte function, while amyloid deposits disrupt the structure and function of the heart. Current treatments focus on reducing light chain production with plasma cell-directed therapies and managing organ complications, leaving patients with a substantial need for complementary approaches that directly address light chain toxicity and improve organ outcomes.

SOURCE Protego Biopharma

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302924480
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): The TARGET contains an unsupported factual claim: 'weeks after the FDA cleared the company.' The SOURCE only states the FDA clearance was 'recently announced' and provides no specific timing. Remove or revise this phrase to match the SOURCE.
Source Name
Unknown Company
Original Summary

<p>- Phase 1 results in healthy volunteers characterize the clinical profile of PROT-001, an investigational first-in-class lambda light chain kinetic stabilizer - Preclinical presentations to evaluate PROT-001's potential to reduce light chain-induced cardiac toxicity in AL amyloidosis and...</p>

Image URL
https://mmx.prnewswire.com/media/MS1763404/Protego-Logo-Logo.jpg?id=OA3046110&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Protego to Present Five PROT-001 Datasets at ISA 2026 After FDA Nod", "body_html": "<p><strong>SAN DIEGO -- [CURRENT_DATE] --</strong> Protego Biopharma will present five datasets on its lead candidate PROT-001 at the XX International Symposium on Amyloidosis (ISA 2026) on November 15-18, 2026, weeks after the FDA cleared the company to start its Phase 2/3 SHIELD-AL study in AL amyloidosis.</p><p>The program includes four discussed E-poster presentations and one traditional poster. SHIELD-AL will test PROT-001 added to standard of care in AL amyloidosis patients.</p><h5>Phase 1 data in healthy volunteers headline the program on November 16</h5><p>Protego will present results from the Phase 1 PRO-1A-101 study (abstract 32458) on Monday, November 16, from 10:35 to 11:00 AM in E-poster Session 1. PRO-1A-101 was a first-in-human, randomized, double-blind, placebo-controlled, four-part study in healthy adults. It evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, food effect and drug-drug interaction potential. The study is registered as NCT06981299.</p><p>PROT-001 is described as a first-in-class lambda light chain kinetic stabilizer. It is an investigational small-molecule pharmacological chaperone.</p><h5>Preclinical work targets cardiac toxicity and bortezomib compatibility</h5><p>Three presentations are scheduled for Tuesday, November 17, from 11:00 AM to 12:00 PM in E-poster Session 10:</p><ul><li>Abstract 32147 reports that PROT-001 is compatible with bortezomib-based regimens while preserving plasma cell cytotoxicity.</li><li>Abstract 32266 reports that PROT-001 suppresses amyloidogenic light chain-induced BNP signaling and cardiotoxicity in human cardiomyocytes.</li><li>Abstract 32645 describes AmyLiteDx, a mass spectrometry-based platform for analyzing amyloidogenic immunoglobulin light chains in AL amyloidosis.</li></ul><p>A fifth presentation (abstract 32646), a retrospective study of cardiac biomarkers in patients with AL cardiac amyloidosis, will appear in the General Poster Session on November 17.</p><h5>Protego pitches PROT-001 as a complement to plasma cell-directed therapy</h5><p>CEO Brent J. Warner described PROT-001 as \"a distinct approach that could complement therapies directed at the plasma cells that produce them.\" He said the company believes the approach could help patients achieve faster and deeper organ responses beyond standard of care alone. He added that deeper cardiac responses are associated with improved survival.</p><p>Current AL amyloidosis treatments reduce light chain production with plasma cell-directed therapies and manage organ complications. The disease affects more than 5,100 newly diagnosed patients annually and 28,000 US adults. Toxic light chains can directly impair cardiomyocyte function, while amyloid deposits disrupt the structure and function of the heart.</p>", "meta_description": "Protego Biopharma will present five datasets on PROT-001 at ISA 2026 on Nov. 15-18, including Phase 1 results, after FDA cleared its Phase 2/3 SHIELD-AL study.", "seo_keywords": "Protego Biopharma, PROT-001, AL amyloidosis, ISA 2026, SHIELD-AL, light chain stabilizer, AmyLiteDx, bortezomib, Phase 2/3, protein misfolding", "companies": ["Protego Biopharma"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["event_participation", "clinical_trial_update"], "products": ["PROT-001"], "themes": ["clinical_development", "rare_disease", "diagnostics"], "events": ["XX International Symposium on Amyloidosis (ISA 2026)"], "cta_text": "Learn more about Protego Biopharma and its PROT-001 program", "learn_more": "https://www.protegobio.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
706714212055e323247d490817ba4885
Verdera Energy Corp. Receives TSX Venture Exchange Approval for New Normal Course Issuer Bid
Image File
Original HTML

TSXV: V

OTCQB: VUECF

www.verderauranium.com

VANCOUVER, BC, Nov. 2, 2026 /PRNewswire/ -- Verdera Energy Corp. (TSXV: V) (OTCQB: VUECF) (the "Company" or "Verdera") announced today that it will establish a new normal course issuer bid (the "New NCIB"), reflecting the Company's expanded capitalization following the distribution of Verdera common shares to shareholders of enCore Energy Corp., and providing for an increase in the maximum number of common shares that may be purchased for cancellation. In connection with the New NCIB, the Company terminated its existing normal course issuer bid (the "Previous NCIB"), which commenced on September 29, 2026 and ended on October 30, 2026.

Under the Previous NCIB, the Company was authorized to purchase for cancellation up to 3,793,152 common shares, representing approximately 10% of its public float of 37,931,520 common shares and approximately 5% of its 75,782,993 issued and outstanding common shares as of September 23, 2026. The Company purchased an aggregate of 380,500 common shares under the Previous NCIB, which have been cancelled.

Following the termination of the Previous NCIB and the cancellation of all 380,500 common shares purchased thereunder, the Company had 110,412,493 common shares issued and outstanding and a calculated public float of 67,695,476 common shares. These figures reflect the reduction from 110,792,993 common shares issued and outstanding and a public float of 68,075,976 common shares immediately prior to the cancellation of shares purchased under the Previous NCIB.

Under the New NCIB, the Company intends to purchase for cancellation up to 6,389,047 common shares, representing approximately 9.44% of the adjusted public float and 5.79% of the adjusted issued and outstanding common shares. The proposed maximum takes into account the 380,500 common shares purchased for cancellation under the Previous NCIB. Accordingly, the aggregate maximum number of common shares purchased or eligible for purchase under both NCIBs would be 6,769,547 common shares, representing approximately 10% of the adjusted public float.

Purchases under the New NCIB may commence through the facilities of the TSXV on or after November 6, 2026 and will terminate on the earlier of (i) November 5, 2027, (ii) the date on which the Company has purchased the maximum number of common shares permitted under the New NCIB, or (iii) the date on which the Company elects to terminate the New NCIB.

The Company has retained Haywood Securities Inc. to act as its designated broker to effect purchases under the New NCIB. Purchases will be conducted on the open market through the facilities of the TSXV at prevailing market prices at the time of acquisition, subject to the pricing and other limitations prescribed by TSXV policies. All common shares purchased under the New NCIB will be cancelled.

The Company terminated the Previous NCIB and is establishing the New NCIB to reflect changes to its issued and outstanding share capital and public float following the conversion of 35,000,000 Class A preferred shares into common shares in connection with the distribution of Verdera common shares to shareholders of enCore Energy Corp.

The distribution of 35,000,000 common shares to shareholders of enCore Energy Corp., completed on September 30, 2026, was a predetermined share issuance at the time the Company launched the Previous NCIB. The Company set the maximum number of common shares available for purchase under the Previous NCIB based on its capitalization and public float immediately prior to the distribution, rather than on its capitalization and public float giving effect to the distribution, as an administrative oversight. The New NCIB addresses this by resetting the maximum to reflect the Company's updated capitalization, with the 380,500 common shares purchased under the Previous NCIB deducted from the maximum number of common shares available for purchase under the New NCIB, in accordance with applicable TSX Venture Exchange requirements.

The New NCIB is consistent with the Company's belief that the purchase of its common shares at prevailing market prices may represent an attractive and appropriate use of available capital. The timing and extent of purchases will depend on market conditions, available funds and other corporate considerations, as determined by management. The Company is not obligated to purchase any common shares under the New NCIB and may suspend or terminate purchases at any time.

The Previous NCIB commenced on September 29, 2026 and was originally scheduled to expire on September 28, 2027. The Company terminated the Previous NCIB on October 30, 2026. As of October 30, 2026, the Company had purchased 380,500 common shares under the Previous NCIB at an average price of $0.2611 per common share, for total consideration of approximately $99,356.08, excluding brokerage commissions.

About Verdera Energy Corp.

Verdera Energy Corp. is focused on the development of In-Situ Recovery ("ISR") uranium assets in New Mexico. Led by a team with extensive experience in the uranium and natural resources sector, Verdera is working to meet the growing demand for clean, reliable domestic uranium in the United States. Verdera holds private mineral rights spanning approximately 400 square miles, 88 million pounds of known and historical resources and a significant proprietary uranium database. New Mexico, with expansive uranium resources, is positioned as a critical district in the U.S. domestic nuclear renaissance, driven by efforts to reduce reliance on foreign imports. Verdera is committed to fostering strong community relations and strives to work closely with local communities.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward Looking Statements:

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws that are based on management's current expectations, assumptions and beliefs. Forward-looking statements can often be identified by such words as "anticipates", "will", "may", "expects", "plans", "believes", "intends", "estimates", "projects", "continue", "potential", and similar expressions or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may", "could", or "will" be taken.

Forward-looking statements and information that are not statements of historical fact include, but are not limited to, statements regarding the anticipated termination of the Previous NCIB, the establishment and commencement of the New NCIB, the maximum number of common shares that may be purchased, the timing and extent of purchases under the New NCIB, and the Company's intentions regarding the use of available corporate funds. Such statements are based on management's current expectations and assumptions, including prevailing market conditions, the availability of sufficient funds and compliance with applicable TSXV requirements. Forward-looking statements are not guarantees of future results and are subject to important risks and uncertainties, many of which are beyond the Company's control.

A number of important factors could cause actual results or events to differ materially from those indicated or implied by such forward-looking statements, including without limitation the risk that the occurrence of any event,; and factors relating to forward-looking statements listed above which include risks as disclosed in Verdera's filings on SEDAR+ and with the SEC. Should one or more of these risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Verdera assumes no obligation to update the information in this communication, except as required by law. Additional information identifying risks and uncertainties is contained in filings by Verdera with the respective securities commissions which are available online at www.sec.gov and www.sedarplus.ca.

Forward-looking statements are provided for the purpose of providing information about the current expectations, beliefs and plans of management. Such statements may not be appropriate for other purposes and readers should not place undue reliance on these forward-looking statements, that speak only as of the date hereof, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Verdera Energy Corp.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302925858
Press Eligible
Yes
Press Eligible Reason
Manuelle Prüfung nötig. Risiko: MEDIUM. Flags: ['finance', 'numbers']. Stichprobe: False
Source Name
Unknown Company
Original Summary

<p>TSXV: V OTCQB: VUECF www.verderauranium.com VANCOUVER, BC, Nov. 2, 2026 /PRNewswire/ -- Verdera Energy Corp. (TSXV: V) (OTCQB: VUECF) (the "Company" or "Verdera") announced today that it will establish a new normal course issuer bid (the "New NCIB"), reflecting the Company's expanded...</p>

Image URL
https://mmx.prnewswire.com/media/MS1845229/Verdera-Energy-Corp-Verdera-Energy-Corp-Receives-TSX-Venture-E.jpg?id=OA3051429&p=facebook
Content Hash (SHA-256, erste 32 hex)
c8e4efaff55f3927fd1b6c17f13b2c5d